, and genes. Based on all these factors, breast cancer risk assessment can be difficult, but is necessary to provide women with the most accurate estimate of their risk and the most appropriate risk management options. The NCCN Clinical Practice
Search Results
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar
, including prevention, screening, and treatment. NCCN Clinical Practice Guidelines in Oncology : Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014 Version 1.2014, 02-28-14 ©2014 National Comprehensive Cancer Network, Inc. All
Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Travis Bray, Jamie A. Cannon, Gregory Cooper, Donald S. David, Dayna S. Early, Deborah Erwin, James M. Ford, Francis M. Giardiello, William Grady, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Scott E. Regenbogen, Niloy Jewel Samadder, Moshe Shike, Gideon Steinbach, David Weinberg, Mary Dwyer, and Susan Darlow
; or Family history of Lynch syndrome-associated cancers. NCCN criteria for further risk evaluation among individuals unaffected by cancer include a NCCN Clinical Practice Guidelines in Oncology : Genetic/Familial High-Risk Assessment
Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher, and Jeffrey N. Weitzel
, screening, and treatment. NCCN Clinical Practice Guidelines in Oncology : Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2010, 03-08-10 ©2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar, and Susan Darlow
of this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian Describe the rationale behind the decision-making process for
Samir Gupta, Dawn Provenzale, Scott E. Regenbogen, Heather Hampel, Thomas P. Slavin Jr, Michael J. Hall, Xavier Llor, Daniel C. Chung, Dennis J. Ahnen, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Amy L. Halverson, Stanley R. Hamilton, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Arnold J. Markowitz, Robert J. Mayer, Reid M. Ness, Niloy Jewel Samadder, Moshe Shike, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer, and Ndiya Ogba
Genetic/Familial High-Risk Assessment: Colorectal Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal NCCN Guidelines Insights : Genetic
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
to NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian
Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel
R apidly evolving genetic and genomic technologies for genetic cancer risk assessment (GCRA) are revolutionizing the approach to targeted therapy and cancer screening and prevention, heralding the era of personalized medicine. Although academic
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo
pharmacologic VTE prophylaxis reported a VTE rate of 4.1 per 100 patient-months. 2 To prevent IMiD-associated VTE in patients with MM, experts from the International Myeloma Working Group (IMWG) proposed a VTE risk assessment consensus guide that incorporated
Alok A. Khorana
individual cancer patients or in specific settings therefore becomes especially important to applying targeted thromboprophylaxis. Knowledge gained within the past decade has improved understanding of risk assessment and prophylaxis of cancer-associated VTE
